Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01)
收藏NIAID Data Ecosystem2026-03-13 收录
官方服务：
资源简介：
This is a Phase 1/2, first-in-human, open-label, dose escalation and dose-expansion study of E-602, administered alone and in combination with cemiplimab.
创建时间：
2022-02-15
